Company overview
ImmuneOnco Biopharmaceuticals (Shanghai) Co.,Ltd., founded in June 2015 in Zhangjiang High-Tech Park of Shanghai, China, is an early-stage biopharmaceutical company dedicated to development and commercialization of novel cancer immunotherapeutics that reverse cancer cell-induced immune inhibition and actively eradicate cancer cells.
News Center
-
11-052021ADCC-enhanced CTLA-4 Antibody of ImmuneOnco Received Approval of NMPA for Clinical TrialOn November 4, 2021, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced that IMM27M, the newly developed ADC......See details
-
10-262021The first patient in the Phase Ib trial of IMM01 successfully enrolledOctober 27, 2021, Shanghai, China. ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced that IMM01, the drug ca......See details
-
09-292021ImmuneOnco won the "Top 20 Innovation and Entrepreneurship in Pudong New Area in 2020"On the September 29, 2021, Pudong New Area held commendation event for "2021 Outstanding Economic Contribution Enterpr......See details